Cardlytics (CDLX) Q1 2026 Earnings Transcript

Cardlytics reported steep year-over-year declines in Q1 billings (-37% to $58.1M), revenue (-39% to $34.3M), and adjusted contribution (-28% to $19.7M), largely due to Bank of America’s exit and supply constraints. Offsetting that, adjusted EBITDA turned positive at $0.2M, adjusted operating expenses fell 38%, and free cash flow improved to -$7.9M as the company continued cost reductions and liquidity improvement after the Bridg sale. Q2 guidance calls for sequential growth, with billings of $61M-$67M and revenue of $35M-$40M, while management flagged ongoing pressure in travel and hospitality and a likely decline in adjusted contribution margin after Bridg divestiture.

Analysis

The core setup is not a simple turnaround; it is a rightsized asset with a shrinking addressable base trying to reprice itself as a self-funding niche platform. The near-term winners are the remaining banking and advertiser partners that benefit from a thinner cost structure and better operating leverage, while the biggest loser is the company’s own top-line optionality if supply does not re-accelerate after the single-customer reset. The most important second-order effect is that a lower fixed-cost base can make modest sequential growth look like a much larger earnings inflection, even if absolute monetization per user remains under pressure.

The market is likely underestimating how much of the near-term narrative is now about mix, not growth. U.K. strength and newer FI partner programs can offset some U.S. softness, but they also tend to carry different monetization profiles and may not fully replace the lost density from the departed large bank. That means the equity can work on multiple compression if management proves sustained sequential improvement, but it remains fragile if travel/hospitality budgets stay delayed into the next 1-2 quarters.

The contrarian angle is that the Bridge divestiture may be more bullish for survival than for valuation, because it converts a messy integration story into a cleaner operating model and reduces the chance of continued cash bleed. Still, the current quarter likely represents the easiest comp of the year; if sequential guidance is missed once, the market will quickly reprice the stock as a melting-ice-cube rather than a self-help story. The real catalyst window is the next two quarters: either CRP and new FI supply show tangible monetization, or the stock will likely trade back on cash runway and customer concentration risk.

Key Decisions for Investors

• Avoid initiating a naked long ahead of the next print; if trading CDLX, prefer a 1-2 quarter call spread only after evidence of sequential billings stabilization. Upside is meaningful if the market believes the self-help story, but downside is sharp if guidance confidence slips.
• Pair trade: long PAR vs short CDLX over the next 1-3 months. PAR benefits from monetization of divested assets/liquidity cleanup, while CDLX still carries execution risk from customer concentration and supply recovery.
• For event-driven investors, consider a small speculative long in CDLX only on a post-earnings pullback if the stock de-risks on cash burn and debt reduction. Risk/reward improves if it trades below levels implying less than 1x forward revenue with cash runway concerns already priced in.
• Sell downside via put spreads rather than buying stock outright if you believe management can hit the low end of Q2 guidance. The thesis is that the market overfocuses on y/y declines and underweights the lower cost base, but downside remains severe if pipeline softness persists.
• Watch BAC as an indirect negative read-through for partner concentration in card-linked offers; if other large financial partners show similar budget behavior, CDLX’s recovery path lengthens materially over the next 6-12 months.